...
首页> 外文期刊>Methods: A Companion to Methods in Enzymology >SDR grafting--a new approach to antibody humanization.
【24h】

SDR grafting--a new approach to antibody humanization.

机译:SDR嫁接-一种抗体人源化的新方法。

获取原文
获取原文并翻译 | 示例

摘要

A major impediment to the clinical utility of the murine monoclonal antibodies is their potential to elicit human anti-murine antibody (HAMA) response in patients. To circumvent this problem, murine antibodies have been genetically manipulated to progressively replace their murine content with the amino acid residues present in their human counterparts. To that end, murine antibodies have been humanized by grafting their complementarity determining regions (CDRs) onto the variable light (V(L)) and variable heavy (V(H)) frameworks of human immunoglobulin molecules, while retaining those murine framework residues deemed essential for the integrity of the antigen-combining site. However, the xenogeneic CDRs of the humanized antibodies may evoke anti-idiotypic (anti-Id) response in patients. To minimize the anti-Id response, a procedure to humanize xenogeneic antibodies has been described that is based on grafting, onto the human frameworks, only the specificity determining residues (SDRs), the CDR residues that are most crucial in the antibody-ligand interaction. The SDRs are identified through the help of the database of the three-dimensional structures of the antigen-antibody complexes of known structures or by mutational analysis of the antibody-combining site. An alternative approach to humanization, which involves retention of more CDR residues, is based on grafting of the 'abbreviated' CDRs, the stretches of CDR residues that include all the SDRs. A procedure to assess the reactivity of the humanized antibody to sera from patients who had been administered the murine antibody has also been described.
机译:鼠单克隆抗体临床应用的主要障碍是它们在患者中引起人抗鼠抗体(HAMA)反应的潜力。为了避免这个问题,已经对鼠抗体进行了基因操作,以用其人类对应物中存在的氨基酸残基逐渐取代其鼠内容物。为此,已经通过将互补决定区(CDR)嫁接到人免疫球蛋白分子的可变轻链(V(L))和可变重链(V(H))框架上,而保留了那些被认为是鼠类框架残基的鼠源化抗体对于抗原结合位点的完整性至关重要。但是,人源化抗体的异种CDR可能引起患者的抗独特型(anti-Id)反应。为了最小化抗Id反应,已经描述了一种将异种抗体人源化的方法,该方法基于仅将特异性决定残基(SDR),在抗体-配体相互作用中最关键的CDR残基嫁接到人框架上。通过已知结构的抗原-抗体复合物的三维结构的数据库的帮助,或通过抗体结合位点的突变分析,可以确定SDR。人源化的另一种方法,涉及保留更多的CDR残基,是基于“缩写” CDR(包括所有SDR的CDR残基片段)的移植。还描述了评估人源化抗体对已施用鼠抗体的患者血清反应性的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号